The Asthma and Allergy Foundation of America (AAFA) continues to push for efforts to lower the cost of asthma medicines, such as inhalers. We know the high cost of medicine can be a barrier to treatment. AAFA welcomes the news that AstraZeneca is lowering the out-of-pocket cost of its inhaled respiratory products to $35 a month. The covered products include: AIRSUPRA® (albuterol and budesonide) inhalation aerosol BEVESPI AEROSPHERE® (glycopyrrolate and formoterol fumarate) inhalation aerosol…
Lesen Sie weiter auf: Drug Maker to Reduce Cost of Asthma Inhalers
Quelle: Asthma and Allergy Foundation of America
Titelbild/Grafik by Asthma and Allergy Foundation of America (AAFA)
Kommentare und Fragen
Möchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!Weiteres von Asthma and Allergy Foundation of America
- Learn About Getting Control of Moderate-to-Severe Asthma - Videos
- Find Out If Your Home Is Asthma and Allergy Friendly with Our Healthier Home Assessment
- EPA's New Vehicle Emissions Standards Will Help Millions of People with Asthma
- April Research Update: Asthma Clinical Trial, Treatment for Severe Asthma, Asthma Care Gaps
- Teva’s Digihaler Products to Be Discontinued
- AAFA to President Biden: Please Recognize May as National Asthma and Allergy Awareness Month
- National Healthy Schools Day Highlights the Need for Better School Environments for Children with Asthma
- If You Have a Shellfish Allergy, Don’t Eat Cicadas No Matter How Tasty They May Look
- AAFA Leads the Way to Lower Costs of Asthma Inhalers
- National Healthy Homes Month: The Connection Between Your Home and Your Health
